Cue Biopharma Inc (CUE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.44-0.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CUE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.6% |
| Our one-year growth estimate | diamond | -62.5% |
Growth built into the price is above our model estimate.
The price assumes 4.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
CUE — private placement
Dated 2026-07-10
Entry into a Material Definitive Agreement. On July 9, 2026, Cue Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with accredited investors (the “Investors”), including Cormorant Asset Management and Columbia Threadneedle Investments, pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of (i) 1,418,071 shares of the Company’s common stock, par value $0.001 per share (the “Common St…
Why it matters: If health care revenue growth picks up, it could benefit Cue. This is key for future performance.
Supportive ifHealth care revenue growth exceeds 10% year over year.
Worry ifHealth care revenue growth remains below 10% year over year.
Why it matters: Progress on these drugs is key to Cue Biopharma's future. It shows the company's ability to advance its pipeline.
Supportive ifManagement says they have made good progress on clinical milestones for CUE-221 and CUE-401.
Worry ifNo updates or negative news on clinical milestones for CUE-221 and CUE-401.
Why it matters: Results from this study will impact Cue's plans for CUE-221 and its market potential.
Supportive ifThe Phase 2 CSU study in China had positive results. This shows it works well.
Worry ifNegative or inconclusive results from the Phase 2 CSU study.
Why it matters: This data will show how well CUE-221 works for chronic spontaneous urticaria. Positive results could boost confidence in the drug's potential.
Supportive ifCUE-221 Phase 2 data shows good results.
Worry ifCUE-221 Phase 2 data shows poor results or safety problems.
Why it matters: The IND submission for CUE-401 is a key step in advancing its development for autoimmune diseases. This could signal progress in the pipeline.
Supportive ifSubmission of the IND for CUE-401 to the FDA by the end of 2026.
Worry ifDelay in the IND submission for CUE-401 beyond the year-end 2026 timeline.
Why it matters: Progress in this partnership may lead to new product developments and revenue streams.
Supportive ifNew compounds are shared for development in the partnership.
Worry ifNo updates or bad news about the partnership.
Why it matters: Cash position updates will show if Cue can pay for its clinical goals until early 2027.
Watch forThe private placement confirms that cash runway is extended. This will help support clinical trials.
Also watch forReports say there is not enough cash to keep operations or clinical trials going.
Why it matters: This data could validate Cue's strategy and enhance its portfolio. Positive results could attract more investment.
Watch forAscendant Health's Phase 2 data shows positive results for CUE-221.
Also watch forAscendant Health's Phase 2 data shows bad or unclear results.
Why it matters: Starting this trial shows Cue is making progress. It may help Cue grow in the market.
Supportive ifThe global Phase 2b trial in food allergy is starting. This follows the CSU study results.
Worry ifDelay or cancellation of the Phase 2b trial initiation.
Why it matters: This study's data could help us understand CUE-221's effectiveness in another market. It may affect future plans.
Watch forPositive results from Ascendant Health's ongoing Phase 2 study in China.
Also watch forNegative or inconclusive results from the Phase 2 study.
Why it matters: This partnership is crucial for CUE-221's development. Positive updates could enhance growth prospects.
Watch forGood news on the Ascendant Health partnership can increase revenue.
Also watch forBad news or delays in the Ascendant Health partnership can hurt revenue.
Why it matters: The company's cash affects its ability to run operations. Good cash flow shows stability.
Watch forCash and cash equivalents rise after the recent $50 million funding.
Also watch forCash position falls or is not enough to run operations.
Why it matters: Data from this study could confirm the value of the licensing agreement. It may also impact future partnerships.
Supportive ifPhase 2 study data is released by the end of Q3 2026.
Worry ifPhase 2 study data is delayed beyond Q3 2026.
Why it matters: Changes in leadership can change strategy and operations. This matters for investor trust.
Watch forAnnouncement of a new executive with a strong track record in biopharma.
Also watch forMore top executives might leave. There is also confusion about what management plans to do.
Why it matters: Finishing this study would help Cue's finances and support clinical work. This is important for operations.
Supportive ifThe $50 million private placement has closed.
Worry ifFailure to complete the private placement as planned.
Why it matters: The plan's success could impact employee retention and motivation. This is key for Cue's growth.
Watch forEmployees and analysts give positive feedback about the 2026 Stock Incentive Plan. They say it helps morale.
Also watch forThere are bad reports about workers unhappy with the 2026 Stock Incentive Plan.
Why it matters: This data will show if CUE-221 works for chronic spontaneous urticaria. Good results could help investors feel more confident.
Supportive ifCUE-221 Phase 2 data shows good results in chronic spontaneous urticaria.
Worry ifCUE-221 Phase 2 data fails to show positive efficacy results.
Why it matters: Starting this study would show progress in Cue's work on autoimmune diseases. Delays could worry investors about execution.
Supportive ifCUE-401 Phase 1 study has started and been announced.
Worry ifCUE-401 Phase 1 study is delayed or not initiated by year-end 2026.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$534 on $10,000 · ±5.3% | How much price usually moves either way. |
| Bad day | $1,353 loss on $10,000 · 13.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,089 loss on $10,000 · 80.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.